J Gerry Kenna

List of Publications by Year
in descending order

19 papers	744 citations	623188 14 h-index	610482 24 g-index
28 all docs	28 docs citations	28 times ranked	813 citing authors

#	Article	IF	Citations
1	A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment. Regulatory Toxicology and Pharmacology, 2022, 129, 105094.	1.3	29
2	Use of in vitro metabolism and biokinetics assays to refine predicted in vivo and in vitro internal exposure to the cosmetic ingredient, phenoxyethanol, for use in risk assessment. Regulatory Toxicology and Pharmacology, 2022, 131, 105132.	1.3	3
3	Read-across and new approach methodologies applied in a 10-step framework for cosmetics safety assessment â€“ A case study with parabens. Regulatory Toxicology and Pharmacology, 2022, 132, 105161.	1.3	18
4	New framework for a non-animal approach adequately assures the safety of cosmetic ingredients â€“ A case study on caffeine. Regulatory Toxicology and Pharmacology, 2021, 123, 104931.	1.3	21
5	Advancing nonclinical innovation and safety in pharmaceutical testing. Drug Discovery Today, 2019, 24, 624-628.	3.2	9
6	Systems toxicology: modelling biomarkers of glutathione homeostasis and paracetamol metabolism. Drug Discovery Today: Technologies, 2015, 15, 9-14.	4.0	6
7	Current Concepts in Drugâ€Induced Bile Salt Export Pump (BSEP) Interference. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2014, 61, 23.7.1-15.	1.1	18
8	Glutathione metabolism modeling: A mechanism for liver drug-robustness and a new biomarker strategy. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 4943-4959.	1.1	28
9	Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. Integrative Biology (United Kingdom), 2013, 5, 877-888.	0.6	34
10	Assessment of gadoxetate DCEâ€MRI as a biomarker of hepatobiliary transporter inhibition. NMR in Biomedicine, 2013, 26, 1258-1270.	1.6	44
11	Bioactivation of the Cannabinoid Receptor Antagonist Rimonabant to a Cytotoxic Iminium Ion Metabolite. Chemical Research in Toxicology, 2013, 26, 124-135.	1.7	18
12	Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification. Drug Metabolism and Disposition, 2012, 40, 2332-2341.	1.7	77
13	Characterization of THLE-Cytochrome P450 (P450) Cell Lines: Gene Expression Background and Relationship to P450-Enzyme Activity. Drug Metabolism and Disposition, 2012, 40, 2054-2058.	1.7	18
14	Systems biology tools for toxicology. Archives of Toxicology, 2012, 86, 1251-1271.	1.9	41
15	In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chemical Research in Toxicology, 2012, 25, 1616-1632.	1.7	197
16	Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chemico-Biological Interactions, 2011, 192, 65-71.	1.7	90
17	Cell based approaches for evaluation of drug-induced liver injury. Toxicology, 2010, 268, 125-131.	2.0	71
18	Biochemical and toxicological consequences of methapyrilene bioactivation. Toxicology, 2007, 240, 154-155.	2.0	0

#	Article	IF	Citations
19	A novel method for quantification of canalicular transporter inhibition in primary rat hepatocyte sandwich cultures. Toxicology, 2006, 226, 66-67.	2.0	3